Sofosbuvir/daclatasvir

Daclatasvir/sofosbuvir (trade names Darvoni, Sovodak) is a two-drug combination for the treatment of hepatitis C.^[2] It is given as a single daily pill containing daclatasvir, a viral NS5A inhibitor,^[3] and sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase NS5B.^[4]

Sofosbuvir/daclatasvir

Sovodak 60/400
Combination of
Daclatasvir	NS5A inhibitor
Sofosbuvir	NS5B (RNA polymerase) inhibitor
Clinical data
Trade names	Darvoni,[1] Sovodak
Routes of administration	Oral
Identifiers
CAS Number	2306918-02-3

It is on the World Health Organization's List of Essential Medicines.^[5]

Society and culture

This combination is produced by an Iranian company under the trade name of Sovodak.^[6] The combination includes 400 mg sofosbuvir and 60 mg daclatasvir and has been used in clinical trials since 2015.^[7][8][9] Sovodak was approved by the Iranian Food and Drug Administration in October 2015^[10] and is currently marketed in Iran as the treatment of choice for all genotypes of hepatitis C as recommended by the national Iranian guideline for treating hepatitis C.^[11]

Research

The similarities between the hepatitis C and SARS-CoV-2 virus has led some researches to investigate the effectiveness of sofosbuvir/daclatasvir against COVID-19. Three recently published studies have found this combination to be beneficial against COVID-19 although the findings require confirmation by larger studies.^[12][13][14]

In October 2020, a meta-analysis found a significantly lower risk of all-cause mortality with the drug combination when given to hospitalized patients with COVID-19.^[15]